know compoundsnatamycinpage read from the graph 2026-11-02

Specimen compound organic compoundPlate I

Natamycin

Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis.
Continue
It is used for a variety of fungal infections, mainly topically.”
Definition from MeSH (D010866), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

Formula: C₃₃H₄₇NO₁₃
Molar mass: 665.733 g/mol
ChEBI: CHEBI:7488
PubChem CID: 5284447
MeSH: D010866
InChIKey: NCXMLFZGDNKEPB-FFPOYIOWSA-N

2findings
2endpoints
2papers

Structure

2D depiction · 3D model shown

Loading the model…

PubChem’s computed conformer of natamycin: one low-energy arrangement, not a measurement. Hydrogens are not drawn; the formula counts them.

Class: Organic compound
Formula: C33H47NO13
Mass: 665.733 g/mol
Charge: 0
InChIKey: NCXMLFZGDNKEPB-FFPOYIOWSA-N
SMILES: [H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(=O)O)[C@]([H])(C[C@@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]1O2)O3
Look it up: ChEBI PubChem By InChIKey

Identity from ChEBI, geometry from PubChem. Not evidence.

01 · the evidence, ordered

What the evidence says

: Strong; 0
: Moderate; 0
: Limited; 0
: Very limited; 0
: Insufficient; 2

How to read these marks

Fig. 2 natamycin CHEBI:74882 endpoints 2 findings on ring 1 ring 2 on requestSel natamycin · centre · ring 0

×1.00

Labels

CompoundInspector

natamycin

CHEBI:7488

Open the page

Findings drawn, by strength

2findings · 2 endpoints

Insufficient2

Most findings

ring 0 · 2 endpoints on ring 1

← → round a ring↑ ↓ out and inEnter selecte one more ringf fit to view+ − zoomEsc clearclick a node to select it

Depletes oxalic acid
Inhibits CAT

fig. 3 · 2 endpoints · 2 findings · one mark per findingno endpoint contested

02 · findings

What natamycin moved, and by how much

Dose studied: as its paper gave it. No dose is advised.
Evidence strength: computed from the study. How it is computed

2 rows · 2 findings in the record

CATMoved: inhibitsEffect, as reportednot reportedEvidence: InsufficientPaper: PMID:371751192023
Who
Neofusicoccum parvum, fungal culture
Dose studied
not reported
Furthermore, natamycin can cause oxidative damage to the fungus, as evidenced by decreased superoxide dismutase and catalase enzyme activity.”
Quoted verbatim from Natamycin Has an Inhibitory Effect on Neofusicoccum parvum, the Pathogen of Chestnuts.in vitro · not in humansPermalink
Oxalic acidMoved: depletesEffect, as reportednot reportedEvidence: InsufficientPaper: PMID:380874292024
Who
Sclerotinia sclerotiorum, mycelial culture
Dose studied
not reported
Natamycin markedly disrupted hyphal form, sclerotia formation, integrity of the cell membrane, and reduced the content of oxalic acid and ergosterol, whereas it increased the reactive oxygen species (ROS) and malondialdehyde content.”
Quoted verbatim from Efficacy and toxic action of the natural product natamycin against Sclerotinia sclerotiorum.in vitro · not in humansPermalink

No dose is advised.

03 · figures · 1 plate

Plates

fig. 4natamycin · electrostatic potential, molecular plane · PubChem CID 5284447, computed 3D conformer · MMFF94 partial charges as point charges (approximate) · inside: promolecular density

04 · reach · hypothesis

What it touches on the way

1 entity · assembled from reference reactions

CATProtein1 path · 1 endpointinferred only

05 · interactions

Taken with something else

Documented interactions: None reported

Pairs that share biology

What the reference databases state

Trials · ClinicalTrials.gov: 3without posted results · 3 past the reporting window

All 3 registered trials

Registered, and not reported

Source: ClinicalTrials.gov
Intervention: natamycin
Status: Completed, terminated or suspended
Results posted: No

Trials without posted results

3 trials

3 registered trials without posted results · Overdue (FDAAA 801): 3

3 past the window0 within it, or no actual date

Search this list

NCT06411314completed2023-07-26industrypast the reporting window
NCT05655689completed2023-01-01a university or hospitalpast the reporting window
NCT00516399terminated· The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of povidone-iodine to Natamycin.2010-09a university or hospitalpast the reporting window

06 · the record

What was read to make this page

277

papers screened for natamycin

admitted: 0
read and discarded: 220
not read yet: 57

The screening record, every paper and why

Sources cited

2 papers · 2 findings

2Show every paper cited

Every paper cited, on one page

Other names · 22

antibiotic A-5283 · CL 12,625 · CL 12625 · E 235 · E-235 · pimaricin · pimaricine · tennecetin

systematic · (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0(5,7)]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

systematic · (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

sold as · Delvocid · Delvolan · Delvopos · Mycophyt · Myprozine · Myuprozine · Natacyn · Natajen · Natamatrix · Natamax · Pimafucin · Synogil